What Is Neuroxelin? Dosage, Half-Life & How to Track It

What Neuroxelin is and how it works

Neuroxelin is a synthetic peptide positioned as a neuroprotective compound — something taken to limit damage to brain tissue and support recovery, rather than to treat an active mood or sleep issue the way DSIP or Selank are. It is described as working through mechanisms common to this class of peptide: reducing excitotoxic damage (the cell-damaging cascade triggered by excess glutamate signaling after an injury), calming neuroinflammation, and supporting neural repair processes.

The stated use case is recovery after an acute event — brain injury or stroke — or general cognitive support, with claimed benefits building over consistent daily use across several weeks rather than a single dose.

Worth being direct about this one: independent, peer-reviewed literature specific to Neuroxelin is limited compared to the other peptides in this library — most of what circulates traces back to peptide-vendor dosing guides rather than published research. Treat the mechanism as plausible-sounding (it borrows from well-studied neuroprotective pathways) but not independently verified, and there is no human trial data.

Typical dosing & reconstitution

Neuroxelin is reconstituted from a lyophilized vial with bacteriostatic water and dosed once daily, typically in the morning. A standard starting dose is around 500 mcg, held for about four weeks before any increase toward the upper end of the reported range.

A 48 mg vial reconstituted with 3 mL BAC water gives 16 mg/mL — here’s how the dose tiers map to units:

At 16 mg/mL, 1 unit on a U-100 insulin syringe is about 160 mcg — small enough that a 30- or 50-unit syringe reads more accurately for the lower tiers. The reconstitution calculator handles the concentration math for any vial and water amount.

Half-life & what it means for frequency

There isn’t an independently published half-life for Neuroxelin to cite — pharmacokinetic data this specific hasn’t made it into peer-reviewed literature. The once-daily dosing pattern is a community convention rather than something derived from measured blood levels.

Given its size and similarity to other short synthetic peptides, a short (minutes-to-hours) blood half-life would be a reasonable expectation, but that is an inference from comparable compounds, not a fact established for Neuroxelin itself — worth holding that distinction in mind before treating any number here as settled.

What to track & common side effects

Because independent safety data is limited, there isn’t a well-characterized side-effect profile to point to beyond the general pattern for subcutaneous peptides — injection-site irritation being the most commonly mentioned issue in community reports.

Given the thin evidence base, the most useful thing to track is which tier you’re on and how long you’ve held it, alongside any change in the cognitive or recovery marker that motivated trying it — and any new or unusual symptom, since a compound with this little independent data deserves closer self-monitoring than a well-studied one.

Frequently asked questions